Stockreport

Lyell Immunopharma: LYL314 Drives Momentum Amid Strong ASH Data [Seeking Alpha]

Lyell Immunopharma, Inc.  (LYEL) 
PDF LYL314 achieved a 93% overall response and 76% complete response rate in heavily pre-treated LBCL, positioning LYEL as a differentiated player in CAR T therapies. LYE [Read more]